NASDAQ:ADXSAdvaxis Stock Price, Forecast & News

$0.70

-0.01 (-1.14 %)

(As of 05/28/2020 11:37 AM ET)

Add

Compare

Today's Range

$0.70

Now: $0.70▼

$0.70

50-Day Range

$0.59

MA: $0.68▼

$0.79

52-Week Range

$0.21

Now: $0.70▼

$3.00

Volume2,345 shs

Average Volume1.15 million shs

Market Capitalization$42.29 million

P/E RatioN/A

Dividend YieldN/A

Beta3.6

Advaxis, Inc., a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer. The company is also developing ADXS-PSA for the treatment of prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with OS Therapies LLC; Amgen Inc.; Especificos Stendhal SA de CV; Merck & Co., Inc.; MedImmune/AstraZeneca; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Advaxis.

2.4 Community Rank

Outperform Votes
Advaxis has received 365 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Advaxis has received 407 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Advaxis has received 52.72% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote “Outperform” if you believe ADXS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Advaxis does not currently pay a dividend.
Dividend Growth
Advaxis does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Advaxis insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,588.00 in company stock.
Percentage Held by Insiders
Only 0.26% of the stock of Advaxis is held by insiders.
Percentage Held by Institutions
Only 11.43% of the stock of Advaxis is held by institutions.

0.6 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Advaxis is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Advaxis is -0.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Advaxis has a P/B Ratio of 0.31. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

0.61 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ADXS

Previous Symbol

CUSIPN/A

CIK1100397

Webwww.advaxis.com

Phone609-452-9813

Debt

Debt-to-Equity Ratio0.14

Current Ratio9.26

Quick Ratio9.26

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$20.88 million

Price / Sales2.03

Cash FlowN/A

Price / Cash FlowN/A

Book Value$2.30 per share

Price / Book0.31

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-16,610,000.00

Net Margins-3,108.18%

Return on Equity-82.13%

Return on Assets-70.38%

Miscellaneous

Employees58

Outstanding Shares60,250,000

Market Cap$42.29 million

Next Earnings Date6/8/2020 (Estimated)

OptionableOptionable

Receive ADXS News and Ratings via Email

Sign-up to receive the latest news and ratings for ADXS and its competitors with MarketBeat's FREE daily newsletter.

Advaxis (NASDAQ:ADXS) Frequently Asked Questions

How has Advaxis' stock been impacted by COVID-19 (Coronavirus)?

Advaxis' stock was trading at $0.6666 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ADXS stock has increased by 6.2% and is now trading at $0.7081. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Advaxis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Advaxis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Advaxis.

When is Advaxis' next earnings date?

Advaxis is scheduled to release its next quarterly earnings announcement on Monday, June 8th 2020. View our earnings forecast for Advaxis.

How were Advaxis' earnings last quarter?

Advaxis, Inc. (NASDAQ:ADXS) issued its quarterly earnings results on Friday, March, 13th. The biotechnology company reported ($0.15) earnings per share for the quarter, topping analysts' consensus estimates of ($0.19) by $0.04. Advaxis had a negative return on equity of 82.13% and a negative net margin of 3,108.18%. View Advaxis' earnings history.

Has Advaxis been receiving favorable news coverage?

Media stories about ADXS stock have been trending somewhat negative recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Advaxis earned a media sentiment score of -1.7 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutAdvaxis.

Who are some of Advaxis' key competitors?

Some companies that are related to Advaxis include Sol Gel Technologies (SLGL), Evelo Biosciences (EVLO), Tiziana Life Sciences (TLSA), Mustang Bio (MBIO), Theratechnologies (THTX), Conatus Pharmaceuticals (CNAT), Arbutus Biopharma (ABUS), Trevena (TRVN), IDEAYA Biosciences (IDYA), BIOFRONTERA AG/ADR (BFRA), Zynerba Pharmaceuticals (ZYNE), AVEO Pharmaceuticals (AVEO), Rockwell Medical (RMTI), CELYAD SA/ADR (CYAD) and Sierra Oncology (SRRA). View all competitors.

What other stocks do shareholders of Advaxis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Advaxis investors own include Madrigal Pharmaceuticals (MDGL), Inovio Pharmaceuticals (INO), Merck & Co., Inc. (MRK), Vistagen Therapeutics (VTGN), Anavex Life Sciences (AVXL), Celgene (CELG), Highpower International (HPJ), BIOLINERX LTD/S (BLRX), Novavax (NVAX) and Opko Health (OPK).

Who are Advaxis' key executives?

Advaxis' management team includes the following people:

Mr. Kenneth A. Berlin J.D., Pres, CEO & Director (Age 55)
Ms. Molly Henderson CPA, CPA, MBA, Exec. VP, CFO & Corp. Sec. (Age 48)
Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 59)
Mr. Anthony A. Lombardo, Exec. Officer (Age 70)
Dr. Andres A. Gutierrez, Exec. VP & Chief Medical Officer (Age 58)

What is Advaxis' stock symbol?

Advaxis trades on the NASDAQ under the ticker symbol "ADXS."

Who are Advaxis' major shareholders?

Advaxis' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.41%) and Private Advisor Group LLC (0.33%). Company insiders that own Advaxis stock include Robert Petit and Roni Appel. View institutional ownership trends for Advaxis.

Which institutional investors are buying Advaxis stock?

ADXS stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., and Private Advisor Group LLC. View insider buying and selling activity for Advaxis.

How do I buy shares of Advaxis?

Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Advaxis' stock price today?

One share of ADXS stock can currently be purchased for approximately $0.71.

How big of a company is Advaxis?

Advaxis has a market capitalization of $42.66 million and generates $20.88 million in revenue each year. Advaxis employs 58 workers across the globe.

What is Advaxis' official website?

The official website for Advaxis is www.advaxis.com.

How can I contact Advaxis?

Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff